Summary
Latest filing:
Valetudo Therapeutics LLC is 10% Owner of Liminatus Pharma, Inc. (LIMN). 2 SEC Form 4 filings on record, most recently on 14 July 2026.
Recent Transactions
2Every recent SEC Form 4 transaction Valetudo Therapeutics LLC has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Valetudo Therapeutics LLC's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Ronda E. Stryker - $580.89M of SYK open-market activity in the last 12 months
- Mozart Aggregator II LP - $579.20M of MDLN open-market activity in the last 12 months
- TC Group VII S1, L.L.C. - $554.95M of MDLN open-market activity in the last 12 months
- BERKSHIRE HATHAWAY INC - $473.67M of DVA open-market activity in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $430.69M of PBLS open-market activity in the last 12 months
- Fairmount Funds Management LLC - $399.66M of SYRE open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
What is Valetudo Therapeutics LLC?
Valetudo Therapeutics LLC is a corporate entity, tracked as 10% Owner of Liminatus Pharma, Inc. (LIMN). InsiderAlpha holds 2 primary Form 4 filings for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Valetudo Therapeutics LLC submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Valetudo Therapeutics LLC's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Valetudo Therapeutics LLC and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
